Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

WEDNESDAY, Sept. 18, 2024 (HealthDay News) -- When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cancer-free, a new trial finds.

turning a “cold” tumor to “hot”, enhancing the potential of T cell infiltration and a shift to PD(L)-1 positivity Early signs of efficacy with clinical responses observed with BT-001 in combination ...

Tumors that are dMMR are particularly susceptible to immunotherapy. Continued: The second approval, announced on June 17, is for Merck & Co., Inc.'s pembrolizumab (Keytruda) given along with ...